Video Insights

Roundtable: Focus on Bispecifics in Myeloma
Advertisement
Advertisement
Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
View More
Kenneth Anderson, MDMyeloma | April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Edward Cliff, MDBlood Cancer Talks | April 11, 2024
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Shaikha Alqahtani, MDAcute Myeloid Leukemia | April 10, 2024
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Leah SherwoodAcute Myeloid Leukemia | April 16, 2024
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
Melissa BadamoMyeloma | April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 26, 2024
Dr. Chadi Nabhan brings "The HemOnc Pulse" live to Chicago May 3-4.
Leah SherwoodMyelodysplastic Syndromes | March 25, 2024
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
Tanya Siddiqi, MDChronic Lymphocytic Leukemia | March 29, 2024
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Melissa BadamoMyelodysplastic Syndromes | March 22, 2024
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Melissa BadamoMyeloma | March 13, 2024
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
Melissa BadamoChronic Lymphocytic Leukemia | March 11, 2024
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Justin Taylor, MDChronic Lymphocytic Leukemia | February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
Shambavi Richard, MDVideo Insights | February 8, 2024
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
Mariia Mikhaleva, MDVideo Insights | February 2, 2024
Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award.
Mariia Mikhaleva, MDChronic Lymphocytic Leukemia | January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Dwight Macero, PA-C, MSMyeloma | January 8, 2024
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Advertisement
Advertisement
Editorial Board